Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Other Operating Expenses (2016 - 2025)

Historic Other Operating Expenses for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to $4.6 million.

  • Corcept Therapeutics' Other Operating Expenses rose 6030.69% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.4 million, marking a year-over-year increase of 3657.04%. This contributed to the annual value of $14.0 million for FY2022, which is N/A changed from last year.
  • According to the latest figures from Q3 2025, Corcept Therapeutics' Other Operating Expenses is $4.6 million, which was up 6030.69% from $3.4 million recorded in Q2 2025.
  • Corcept Therapeutics' Other Operating Expenses' 5-year high stood at $4.6 million during Q3 2025, with a 5-year trough of $1.2 million in Q1 2022.
  • Moreover, its 5-year median value for Other Operating Expenses was $1.6 million (2023), whereas its average is $2.0 million.
  • Per our database at Business Quant, Corcept Therapeutics' Other Operating Expenses plummeted by 3248.14% in 2021 and then surged by 8290.04% in 2024.
  • Over the past 5 years, Corcept Therapeutics' Other Operating Expenses (Quarter) stood at $1.4 million in 2021, then rose by 9.31% to $1.5 million in 2022, then rose by 26.82% to $1.9 million in 2023, then surged by 57.49% to $3.0 million in 2024, then skyrocketed by 55.48% to $4.6 million in 2025.
  • Its Other Operating Expenses stands at $4.6 million for Q3 2025, versus $3.4 million for Q2 2025 and $2.4 million for Q1 2025.